Clinical trial
An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS
NCT00002222 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 200
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.